List view / Grid view
The US FDA has granted avatrombopag (Doptelet) ODD as around 10 percent of US cancer patients per year experience chemotherapy-induced thrombocytopenia (CIT) with no available treatment.
The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
A new drug delivery technology has been developed using nanotubes which can efficiently and precisely target lung cancer cells.
A review of a study on children with liver cancer has shown the effectiveness of Transarterial Radioembolization with Yttrium-90 as a course of treatment...
Modern laboratories use a number of gases as part of their daily operations. This application note details two of the most common methods of laboratory gas supply, and their associated safety risks and benefits...
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
Protein inhibits inflammatory response underlying chronic pain processing may provide an alternative to opioids for severe, persistent pain...
A new non-toxic method for delivering anti-cancer drugs to specific parts of the human body could mean the end of the severe side effects...
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
A study has shown that Adipocytes can absorb and metabolise the chemotherapeutic agent daunorubicin, reducing its ability to kill cancer cells.
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
